Executive Summary

PROTAC development has crossed a decisive threshold: the modality now has a marketed drug, several late-stage programs, and human evidence that targeted degradation can be achieved in tumors, blood, skin, and the central nervous system. That progress is material, but it does not establish a class-wide clinical advantage over inhibition, antagonism, or other degrader formats.

The most mature programs remain concentrated around validated targets such as estrogen receptor, androgen receptor, and BTK. Programs aimed at transcription factors, scaffold proteins, mutant RAS, and neurodegenerative targets are scientifically more distinctive, but they remain earlier and carry substantially more biological and translational uncertainty.

Attrition is already informative. Some programs have shown deep target degradation without enough clinical activity, some have encountered safety or manufacturing constraints, and others have been replaced by next-generation molecules or deprioritized for portfolio reasons. The field should therefore stop treating degradation as the development endpoint. The relevant endpoint is a therapeutically useful exposure window in which the right protein is removed, in the right tissue, for the right duration, with a clinically meaningful advantage.

What Counts as a PROTAC

A PROTAC is a heterobifunctional molecule containing a ligand for a protein of interest, a linker, and a ligand for an E3 ubiquitin ligase. Productive ternary-complex formation brings the target and ligase together, leading to ubiquitination and proteasomal degradation. This event-driven mechanism can remove catalytic and non-catalytic functions of a protein, including scaffolding or transcriptional functions that may remain after conventional inhibition. 12

The commercial and clinical vocabulary is broader than the acronym. Sponsors use terms including PROTAC, chimeric degradation activation compound, BiDAC, APTaD, and ligand-directed degrader for related heterobifunctional architectures. Molecular glues and monovalent degraders are part of targeted protein degradation but are mechanistically distinct and are not counted here as PROTAC drugs. The development table therefore includes sponsor-branded heterobifunctional degraders while excluding molecular-glue programs. 132

Published reviews now describe more than 40 degraders, including PROTACs, in clinical testing, with oncology still representing the largest concentration. That count should not be read as a precise number of strict PROTACs because reviews and sponsors differ in how they classify bifunctional degraders, dual degraders, and proprietary induced-proximity formats. 1

The First Approval and What It Actually Proves

On May 1, 2026, FDA approved vepdegestrant, marketed as Veppanu, for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progression following at least one line of endocrine therapy. FDA describes the product as a heterobifunctional protein degrader, and Arvinas identifies it as the first FDA-approved PROTAC. Patient selection requires an FDA-authorized ESR1 test, with Guardant360 CDx approved as the companion diagnostic. 45

In the 624-patient randomized VERITAC-2 trial, 270 patients had ESR1-mutated tumors. In that molecularly defined population, median progression-free survival was 5.0 months with vepdegestrant and 2.1 months with fulvestrant, with a hazard ratio of 0.57, a 95% confidence interval of 0.42 to 0.77, and p=0.0001. Objective response rates were 19% and 4%, respectively. Overall survival was immature, with 16% of deaths observed at the progression-free survival analysis. 4

The approval validates that a large, orally administered heterobifunctional degrader can be manufactured, dosed chronically, evaluated in a conventional randomized trial, paired with a companion diagnostic, and approved on standard clinical evidence. It does not show that the modality is inherently safer or broadly superior. The label includes warnings for QTc prolongation and embryo-fetal toxicity, and the statistically persuasive benefit was confined to the ESR1-mutated population rather than the overall intention-to-treat population. 67

The confirmed marketing authorization in the regulator sources used here is the United States approval of vepdegestrant. Authorization status in other jurisdictions is not established in this article and should not be interpreted as a definitive statement that no other national action has occurred. 4

The Active Clinical Landscape

The current pipeline is no longer a collection of isolated first-in-human experiments. It includes multiple Phase 3 programs, registration-oriented Phase 2 programs, and a broader set of early clinical candidates across oncology, immunology, neurology, and dermatology. The table is a selected landscape of programs with current status supported by primary sponsor or regulator sources, not an exhaustive inventory of every global degrader. 5891011

Late-stage concentration is revealing. Vepdegestrant, BMS-986365, BGB-16673, and bexobrutideg all address targets with established human disease biology and existing pharmacologic validation. Their proposed differentiation is not that the target is newly discovered, but that degradation may overcome resistance mutations, remove non-catalytic functions, or produce a different depth and duration of pathway suppression. 41098

The more ambitious platform thesis is being tested in earlier programs. ARV-806 targets KRAS G12D, ARV-393 targets BCL6, ARV-102 is intended to degrade LRRK2 in the central nervous system, KT-579 targets IRF5, and KT-621 targets STAT6 in chronic inflammatory disease. These programs matter because success would extend PROTAC utility beyond nuclear hormone receptors and BTK, but their clinical evidence remains less mature than the late-stage oncology programs. 511

Global development is also becoming more differentiated by route and geography. GT20029 is a topical androgen-receptor PROTAC with completed Phase 2 acne testing in China, while CFT8919 remains in Phase 1 in Greater China despite C4 Therapeutics' decision not to advance it to the next phase outside that territory at present. These cases show that the worldwide landscape cannot be represented by a single US-centric stage label. 1213

Failures, Stops, and Superseded Programs

A rigorous landscape should not collapse every stopped program into the word failed. The disclosed record contains at least four distinct categories: insufficient clinical efficacy despite target degradation, safety-limited development, strategic discontinuation despite pharmacodynamic activity, and replacement by a next-generation molecule. These categories imply different lessons for the modality. 14151617

CFT8634 is the clearest scientific warning. C4 Therapeutics reported high BRD9 degradation but insufficient single-agent efficacy in heavily pretreated synovial sarcoma and SMARCB1-null tumors, leading the company not to advance the program beyond Phase 1. The result demonstrates that a compelling dependency hypothesis, an apparently druggable degradation mechanism, and deep tumor pharmacodynamics can still fail to produce enough clinical benefit. 14

FHD-609 illustrates a different failure mode. Foghorn paused enrollment after a grade 4 QTc prolongation event at the second-highest dose, and FDA placed the US study on partial clinical hold while permitting patients benefiting from therapy to continue. Foghorn stated that it did not plan to pursue dose expansion independently. The program therefore cannot be interpreted simply as a lack-of-efficacy case. 15

Portfolio substitutions are also scientifically useful. Arvinas prioritized luxdegalutamide over bavdegalutamide for further androgen-receptor development, citing broader mutant coverage and tolerability, while Sanofi and Kymera replaced KT-474 with the next-generation IRAK4 degrader KT-485 based on an improved preclinical profile. These decisions show how quickly a first clinical degrader can become obsolete when mutation coverage, selectivity, distribution, potency, or drug-like properties can be materially improved. 1817

The Scientific Readout

PROTAC pharmacology is governed by a three-body system rather than a conventional binary binding event. Target affinity, E3-ligase affinity, ternary-complex geometry, cooperativity, ubiquitination competence, subcellular colocalization, and target resynthesis all influence the observed effect. A strong binder can therefore be a weak degrader, and a stable ternary complex can still be unproductive if lysine presentation or ubiquitin transfer is unfavorable. 12

The hook effect remains a relevant dose-design risk. At high concentrations, separate target-PROTAC and ligase-PROTAC binary complexes can predominate, reducing productive ternary-complex formation. The clinical consequence is that greater systemic exposure may not produce greater degradation, and dose selection should be based on integrated exposure, target engagement, degradation depth, degradation duration, pathway modulation, and tolerability rather than maximum tolerated dose alone. 12

Medicinal chemistry remains unusually demanding. Many PROTACs occupy beyond-Rule-of-Five chemical space, with high molecular weight, substantial polarity, multiple rotatable bonds, and linker-dependent conformational behavior. Those properties can impair solubility, permeability, oral absorption, metabolic stability, and tissue penetration. The linker and ligase recruiter are not passive appendages: they can alter ternary geometry, pharmacokinetics, neosubstrate degradation, and off-target risk. 32

The NX-2127 manufacturing-related partial clinical hold is a practical reminder that stereochemical and process control can become clinical-development issues. FDA lifted the hold after Nurix introduced a new chirally controlled drug product. This is not evidence of a class-wide defect, but it shows that CMC strategy must be integrated early with molecule selection rather than deferred until late development. 19

E3-ligase choice remains concentrated. Cereblon and VHL dominate published and clinical PROTAC design even though the human ubiquitin system contains a much broader ligase repertoire. This creates both a limitation and an opportunity: ligase expression, localization, essentiality, neosubstrate biology, and resistance mechanisms may constrain activity in specific tissues, while new ligandable ligases could enable tissue selectivity or access to targets that are poorly served by current recruiters. 32

Clinical and Regulatory Implications

The first approval supports a conventional regulatory proposition rather than a modality-specific shortcut. Vepdegestrant was tested against an active comparator in a randomized trial, the approved population was biomarker-defined, and the label requires an FDA-authorized test. The development program succeeded by connecting mechanism to a clinically interpretable resistant-disease population, not by relying on degradation as a surrogate for benefit. 46

For oncology programs, a credible evidence package should distinguish target degradation from downstream pathway suppression and from tumor response. Paired tumor biopsies, circulating tumor DNA, blood or marrow pharmacodynamics, resistance genotyping, and exposure-response analyses can establish that the molecule reached the relevant compartment and produced the intended biology. CFT8634 shows why even strong degradation data cannot substitute for clinical efficacy. 14

For chronic immunology, dermatology, or neurology programs, the development burden is different. KT-621, KT-579, KT-485, ARV-102, and topical GT20029 must support repeated dosing in populations that may have lower tolerance for laboratory abnormalities, cardiac effects, reproductive risk, or off-target degradation than heavily pretreated oncology populations. Central nervous system and topical programs also require route-specific proof of tissue exposure and local target engagement. 1120512

Global programs also require a disciplined status taxonomy. A molecule may be active in one territory, paused in another, or discontinued by one rights holder while a partner continues development. CFT8919 is a current example, with Phase 1 development continuing in Greater China while C4 Therapeutics has elected not to advance the next phase outside Greater China at present. Portfolio databases that assign one global stage without territorial context can therefore materially misstate the asset. 13

What the Landscape Suggests for PROTACs

The next near-term tests are likely to come from programs in which the target and disease are already clinically validated. BMS-986365 is in Phase 3 for metastatic castration-resistant prostate cancer, BGB-16673 has Phase 3 CLL/SLL studies, and Nurix is advancing a registration-oriented Phase 2 and enabling a confirmatory Phase 3 strategy for bexobrutideg. Positive outcomes would broaden validation beyond estrogen receptor degradation, especially if activity is demonstrated in resistance settings where conventional inhibitors have lost effectiveness. 1098

KT-621 may be the most consequential non-oncology readout because it is testing whether an oral STAT6 degrader can compete in chronic type 2 inflammatory disease, where efficacy, convenience, and long-term safety must all be credible. ARV-102 is similarly important because reported cerebrospinal-fluid LRRK2 degradation indicates central target engagement, but the decisive question is whether that pharmacology changes the course or manifestations of neurodegenerative disease. 115

The hardest and most valuable proof remains ahead. Success against KRAS G12D, BCL6, IRF5, or other targets that are poorly addressed by conventional small molecules would demonstrate that PROTACs can expand druggable biology rather than merely create another way to modulate established targets. Failure in those programs would not invalidate degradation, but it would narrow the commercially defensible thesis toward selected targets where resistance coverage, scaffold removal, or pharmacodynamic persistence provides a measurable advantage. 511

The field is therefore moving from modality validation to product differentiation. Future winners will likely combine a biologically privileged target, a demonstrable reason to degrade rather than inhibit, tissue-appropriate ligase biology, tractable oral or local exposure, controllable degradation kinetics, robust CMC, and a clinical design that selects patients most likely to benefit. The first approval removes one existential question, but it raises the standard for every program that follows. 4132

Conclusion

PROTACs are no longer a preclinical concept, but they are not yet a broadly validated therapeutic class. One approval establishes feasibility. Several late-stage programs could establish repeatability. The early pipeline will determine whether the modality can materially expand the set of proteins that can be treated in humans.

The most important lesson from the current record is that degradation is a mechanism, not a value proposition. Deep target knockdown can coexist with weak efficacy, and successful pharmacology can be overtaken by safety, exposure, CMC, or a better molecule. Development programs should be built around a specific clinical advantage that degradation is uniquely positioned to deliver.

The forward outlook is favorable but selective. PROTACs are likely to become an enduring component of drug discovery, particularly where resistance mutations, non-catalytic protein functions, or difficult intracellular targets create a genuine rationale for protein removal. The modality's ultimate scale will depend on how often that rationale survives the full test of human biology.